Dry Weight Reduction Intervention Via Extra Ultrafiltration

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT07637110
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Blood Pressure Management
  • End Stage Renal Disease (ESRD)
  • Fluid Accumulation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ultrafiltration — PROCEDURE
    Ultrafiltration for 4 or 8 weeks compared to no ultrafiltration.

Study Details

Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations. This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Feb 28, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ultrafiltration sessions for 4 weeks
    Two ultrafiltration sessions per week plus pharmacist guided tapering of blood pressure medications in addition to the regular thrice weekly hemodialysis treatments.
  • Active Comparator: Ultrafiltration sessions for 8 weeks
    Two ultrafiltration sessions per week plus pharmacist guided tapering of blood pressure medications in addition to the regular thrice weekly hemodialysis treatments.
  • No Intervention: Control arm, no ultrafiltration sessions
    Participant receives only their regularly scheduled thrice weekly hemodialysis treatments.

Primary Outcome Measure

24-hour continuous ambulatory blood pressure [ Time Frame: Measurement performed at baseline compared to measurement performed at 24 weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northwest Kidney CentersSeattleWashington98112
Luisa Rios-Avila
[email protected]
2062589325

Find similar trials in Seattle, WA

By research site
Northwest Kidney Centers· Seattle, WA

Related Studies